Australian biopharmaceutical company Dimerix Limited is currently developing DMX-200 for respiratory complications in COVID-19 patients with two ongoing Phase 3 clinical trials. The drug is also undergoing a Phase 3 clinical trial for focal segmental glomerulosclerosis disease. Additionally, Dimerix is in the pre-clinical development stage for DMX-700 to treat chronic obstructive pulmonary disease. The company was founded in 2004 and is based in Fitzroy, Australia.
Dimerix Limited's ticker is DXB
The company's shares trade on the ASX stock exchange
They are based in Fitzroy, Australia
There are 1-10 employees working at Dimerix Limited
It is https://dimerix.com/
Dimerix Limited is in the Healthcare sector
Dimerix Limited is in the Biotechnology industry
The following five companies are Dimerix Limited's industry peers: